BOD SCIENCE LIMITED (BOD)
Share Price Analysis and Chart
Enter the company code or Name for stock analysis:
BOD - BOD SCIENCE LIMITED
FNArena Sector :
NONE
Year End: June
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: N/A
Index:
FNArena Sector : NONE
Year End: June
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: N/A
LAST PRICE | CHANGE +/- | CHANGE % | VOLUME |
---|---|---|---|
$0.02
29 Apr |
0.000 OPEN $0.02 |
0.000 HIGH $0.02 |
0 LOW $0.02 |
FNARENA'S MARKET CONSENSUS FORECASTS
- No Record -
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2024 FactSet UK Limited. All rights reserved
Title | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
EPS Basic | xxx | xxx | xxx | xxx | xxx | -5.6 |
DPS All | xxx | xxx | xxx | xxx | xxx | 0.0 |
Sales/Revenue | xxx | xxx | xxx | xxx | xxx | 1.7 M |
Book Value Per Share | xxx | xxx | xxx | xxx | xxx | -0.5 |
Net Operating Cash Flow | xxx | xxx | xxx | xxx | xxx | -5.7 M |
Net Profit Margin | xxx | xxx | xxx | xxx | xxx | -462.88 % |
EPS Basic
DPS All
Sales/Revenue
Book Value Per Share
Net Operating Cash Flow
Net Profit Margin
Title | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Return on Capital Employed | xxx | xxx | xxx | xxx | xxx | -575.61 % |
Return on Invested Capital | xxx | xxx | xxx | xxx | xxx | -575.61 % |
Return on Assets | xxx | xxx | xxx | xxx | xxx | -180.40 % |
Return on Equity | xxx | xxx | xxx | xxx | xxx | -575.61 % |
Return on Total Capital | xxx | xxx | xxx | xxx | xxx | -504.18 % |
Free Cash Flow ex dividends | xxx | xxx | xxx | xxx | xxx | -5.7 M |
Return on Capital Employed
Return on Invested Capital
Return on Assets
Return on Equity
Return on Total Capital
Free Cash Flow ex dividends
Title | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Short-Term Debt | xxx | xxx | xxx | xxx | xxx | 1 M |
Long Term Debt | xxx | xxx | xxx | xxx | xxx | - |
Total Debt | xxx | xxx | xxx | xxx | xxx | 1 M |
Goodwill - Gross | xxx | xxx | xxx | xxx | xxx | - |
Cash & Equivalents - Generic | xxx | xxx | xxx | xxx | xxx | 2 M |
Price To Book Value | xxx | xxx | xxx | xxx | xxx | - |
Short-Term Debt
Long Term Debt
Total Debt
Goodwill - Gross
Cash & Equivalents - Generic
Price To Book Value
Title | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Capex | xxx | xxx | xxx | xxx | xxx | 0.1 M |
Capex % of Sales | xxx | xxx | xxx | xxx | xxx | 8.62 % |
Cost of Goods Sold | xxx | xxx | xxx | xxx | xxx | 5 M |
Selling, General & Admin. Exp & Other | xxx | xxx | xxx | xxx | xxx | 6 M |
Research & Development | xxx | xxx | xxx | xxx | xxx | 3 M |
Investments - Total | xxx | xxx | xxx | xxx | xxx | - |
Capex
Capex % of Sales
Cost of Goods Sold
Selling, General & Admin. Exp & Other
Research & Development
Investments - Total
EXPERT VIEWS
Display All Commentary
Sentiment Indicator
0.0
No. Of Recommendations
0
BOD STOCK CHART
FNArena News on BOD
1 |
Big Pharma Eyeing Oz BiotechsFeb 09 2011 - Australia |
2 |
Southern Cross Sees Upside For bioMD (A Lot)Mar 01 2010 - Australia |